Want to join the conversation?
$MDCO said it closed divestiture of its non-core cardiovascular assets, Cleviprex (clevidipine) injectable emulsion, Kengreal (cangrelor) and rights to Argatroban for Injection to Chiesi USA and its parent company Chiesi Farmaceutici. $MDCO received about $264MM in cash and has potential to receive up to $480MM in sales-based milestone payments.
$TWTR mentions Snap as one of its fiercest rivals in its 10K filing. Great head start for Snap ahead of IPO!